In the treatment of hematological malignancies, the aim to integrate the application of Bcl‐2 inhibitors has led to further research and development of Bcl‐2 selective and dual Bcl‐2 and Bcl‐xL inhibitors. Here, BCL2 is linked to hematologic disorder.